drugset / Trial / NCT01138202
Pharmacokinetics (PK) and Safety of 2 Different Doses of Lopinavir/Ritonavir in in HIV/Tuberculosis (TB) Co-infected Patients Receiving Rifampicin Containing Anti-tuberculosis Therapy
Phase 2
Completed
40 enrolled
The HIV Netherlands Australia Thailand Research Collaboration
Ministry of Health, Thailand · collab
Non-randomizedFactorialOpen-labelOther
Summary
To assess safety, efficacy and impact of Lopinavir/ritonavir 400/100mg bid or Lopinavir/ritonavir 600/150mg bid in combination with rifampicin-containing anti-TB therapy.
Timeline
- Start
- 2010-11
- Primary completion
- 2015-12
- Completion
- 2015-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lopinavir | Other / unclassified | 400 mg | — |
| Subject | Lopinavir | Other / unclassified | 600 mg | — |
| Subject | Ritonavir | Other / unclassified | 100 mg | — |
| Subject | Ritonavir | Other / unclassified | 150 mg | — |